Cullen Capital Management LLC Has $88.32 Million Stake in Pfizer Inc. $PFE

Cullen Capital Management LLC trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 22.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,643,578 shares of the biopharmaceutical company’s stock after selling 1,079,744 shares during the period. Cullen Capital Management LLC’s holdings in Pfizer were worth $88,320,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. GKV Capital Management Co. Inc. bought a new stake in shares of Pfizer during the 1st quarter valued at $27,000. Curio Wealth LLC grew its stake in shares of Pfizer by 36,600.0% during the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,098 shares during the period. Bayforest Capital Ltd bought a new stake in Pfizer in the first quarter valued at about $28,000. Harbor Asset Planning Inc. acquired a new position in Pfizer in the second quarter valued at about $29,000. Finally, Howard Hughes Medical Institute bought a new position in Pfizer during the second quarter worth about $30,000. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Up 0.2%

Pfizer stock opened at $25.86 on Monday. The company has a 50 day moving average of $25.12 and a 200-day moving average of $24.78. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.69. The stock has a market capitalization of $147.04 billion, a PE ratio of 15.04 and a beta of 0.46.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.79 by $0.08. The business had revenue of $16.65 billion for the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio is currently 100.00%.

Analysts Set New Price Targets

A number of brokerages have recently commented on PFE. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $30.00 price target on shares of Pfizer in a research note on Friday, October 31st. Bank of America boosted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Scotiabank started coverage on shares of Pfizer in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 target price for the company. Citigroup began coverage on shares of Pfizer in a research report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price target on the stock. Finally, Guggenheim boosted their price target on shares of Pfizer from $33.00 to $35.00 and gave the company a “buy” rating in a report on Monday, November 24th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $28.33.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.